[go: nahoru, domu]

SG11201802895QA - Antibody/t-cell receptor chimeric constructs and uses thereof - Google Patents

Antibody/t-cell receptor chimeric constructs and uses thereof

Info

Publication number
SG11201802895QA
SG11201802895QA SG11201802895QA SG11201802895QA SG11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA SG 11201802895Q A SG11201802895Q A SG 11201802895QA
Authority
SG
Singapore
Prior art keywords
antibody
cell receptor
chimeric constructs
receptor chimeric
constructs
Prior art date
Application number
SG11201802895QA
Inventor
Jingwei Lu
Zhiyuan Yang
Cheng Liu
Hong Liu
Yiyang Xu
Su Yan
Vivien Wai-Fan Chan
Lucas Horan
Original Assignee
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc
Publication of SG11201802895QA publication Critical patent/SG11201802895QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
SG11201802895QA 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof SG11201802895QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245944P 2015-10-23 2015-10-23
US201662304918P 2016-03-07 2016-03-07
US201662345649P 2016-06-03 2016-06-03
US201662369694P 2016-08-01 2016-08-01
PCT/US2016/058305 WO2017070608A1 (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof

Publications (1)

Publication Number Publication Date
SG11201802895QA true SG11201802895QA (en) 2018-05-30

Family

ID=58558140

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201913247XA SG10201913247XA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913245UA SG10201913245UA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof
SG11201802895QA SG11201802895QA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201913247XA SG10201913247XA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913245UA SG10201913245UA (en) 2015-10-23 2016-10-21 Antibody/t-cell receptor chimeric constructs and uses thereof

Country Status (18)

Country Link
US (6) US11421013B2 (en)
EP (2) EP3842450A1 (en)
JP (3) JP7316042B2 (en)
KR (1) KR20180063325A (en)
CN (4) CN107614519B (en)
AU (2) AU2016342041B2 (en)
CA (1) CA3001137A1 (en)
DK (1) DK3365364T5 (en)
ES (1) ES2979220T3 (en)
HK (2) HK1248243A1 (en)
IL (3) IL314725A (en)
MX (1) MX2018004721A (en)
MY (1) MY194628A (en)
PH (1) PH12018500861A1 (en)
RU (2) RU2022103665A (en)
SG (3) SG10201913247XA (en)
TW (1) TWI780031B (en)
WO (1) WO2017070608A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2762359C2 (en) 2014-12-05 2021-12-20 Мемориал Слоан-Кеттеринг Кэнсер Сентер Chimeric antigenic receptors aimed at receptor bound to g-proteins, and their application
KR102602417B1 (en) * 2014-12-05 2023-11-16 메모리얼 슬로안 케터링 캔서 센터 Antibodies targeting g-protein coupled receptor and methods of use
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
SG10201913247XA (en) 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3516068A4 (en) 2016-09-19 2020-10-14 University of Southern California Non-radioactive cytotoxicity assays
CA3044682A1 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
CA3059753A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
CR20200013A (en) * 2017-07-14 2020-03-11 Immatics Biotechnologies Gmbh POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (sabr)
IL310960A (en) 2017-09-22 2024-04-01 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
SG11202002508XA (en) 2017-09-22 2020-04-29 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
KR20200071079A (en) * 2017-09-27 2020-06-18 유니버시티 오브 써던 캘리포니아 New platform for co-stimulation, new CAR design and other enhancements for adoptive cell therapy
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN109971715A (en) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 A kind of cultural method of specific amplification CAR-T cell
JPWO2019151392A1 (en) * 2018-01-31 2021-02-04 国立大学法人東北大学 Antigen-specific MHC expression regulation method
GB201801920D0 (en) * 2018-02-06 2018-03-21 Autolus Ltd Polypeptides and methods
JP2021514188A (en) 2018-02-15 2021-06-10 メモリアル スローン ケタリング キャンサー センター FOXP3 Target Factor Composition and Usage for Adoptive Cell Therapy
WO2019173837A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
WO2019180724A1 (en) * 2018-03-23 2019-09-26 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
SG11202009525VA (en) * 2018-03-30 2020-10-29 Eureka Therapeutics Inc Constructs targeting cd22 and uses thereof
CN110407927B (en) * 2018-04-26 2022-09-09 香雪生命科学技术（广东）有限公司 TCR (T cell receptor) capable of recognizing AFP (alpha fetoprotein) antigen
WO2019232503A1 (en) * 2018-06-01 2019-12-05 University Of Southern California Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
AU2019288136A1 (en) 2018-06-18 2021-01-07 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
CN110818802B (en) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 Chimeric T cell receptor STAR and application thereof
SG11202102882YA (en) * 2018-09-28 2021-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule comprising altered antibody variable region
EP3880714A4 (en) 2018-11-16 2022-07-20 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
WO2020150364A1 (en) * 2019-01-15 2020-07-23 Altor Bioscience, Llc Human immunodeficiency virus-specific t cell receptors
CN110006724B (en) * 2019-04-17 2021-06-04 郑州安图生物工程股份有限公司 Reagent for detecting trichomonas by adopting papanicolaou and gram staining method
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
WO2021026266A1 (en) * 2019-08-05 2021-02-11 Distributed Bio, Inc. Antigen binding molecules and methods of screening thereof
WO2021030153A2 (en) * 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021046445A1 (en) * 2019-09-05 2021-03-11 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar) that bind bcma
BR112022004458A2 (en) * 2019-09-12 2022-05-31 Tcr2 Therapeutics Inc Compositions and methods for reprogramming tcr using fusion proteins
EP4086281A4 (en) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd Enhanced t-cell receptor star and application thereof
JP2023510353A (en) * 2020-01-10 2023-03-13 ティーシーアール２ セラピューティクス インク． Compositions and methods for autoimmune control
CN111320703A (en) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 Chimeric antigen receptor targeting CD22 and application thereof
KR20220156041A (en) 2020-03-20 2022-11-24 라이엘 이뮤노파마, 인크. Novel recombinant cell surface markers
JP2023524047A (en) 2020-04-28 2023-06-08 ライエル・イミュノファーマ・インコーポレイテッド Cell culture method
US20240148869A1 (en) * 2020-05-07 2024-05-09 China Immunotech (Beijing) Biotechnology Co., Ltd Improved T cell receptor-costimulatory molecule chimera
CN115715299A (en) * 2020-05-25 2023-02-24 华夏英泰（北京）生物技术有限公司 Enhanced synthetic T cell receptor antigen receptors
WO2022164959A1 (en) 2021-01-27 2022-08-04 Lyell Immunopharma, Inc. Improved immune cell therapy
AU2022226660A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Methods for culturing cells
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
TW202309071A (en) 2021-05-05 2023-03-01 德商英麥提克生物技術股份有限公司 Antigen binding proteins specifically binding prame
KR20240038974A (en) * 2021-07-29 2024-03-26 난트셀, 인크. Modified T cell receptors for prevention and treatment of viral infections and cancer
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (en) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド Anti-glycolic LAMP1 antibodies and uses thereof
WO2023070041A1 (en) 2021-10-21 2023-04-27 Lyell Immunopharma, Inc. Enhanced immune cell therapy
IL312302A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods of generating cells
US20230313138A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
US20230310605A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2023133540A1 (en) 2022-01-07 2023-07-13 Lyell Immunopharma, Inc. Il-12 affinity variants
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024100136A1 (en) * 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024103251A1 (en) * 2022-11-15 2024-05-23 原启生物科技(上海)有限责任公司 Anti-afp/hla02 tcr-like antibody and use thereof
WO2024148337A1 (en) * 2023-01-05 2024-07-11 Angeles Therapeutics, Inc. Methods and compositions for gene transduction and to control the activity of synthetic and immune receptors
WO2024148369A1 (en) 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
AU6353596A (en) 1995-06-30 1997-02-05 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-mhc complex
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
IL149809A0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
DK1506236T3 (en) 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
ATE455127T1 (en) 2003-05-31 2010-01-15 Micromet Ag HUMAN ANTI-HUMAN CD3 BINDING MOLECULES
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
AU2006252733A1 (en) * 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to CD20 and uses thereof
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006293420B2 (en) * 2005-09-22 2011-06-30 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
NZ572248A (en) 2006-04-28 2011-08-26 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
US20090304657A1 (en) * 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
AR060871A1 (en) 2006-05-09 2008-07-16 Genentech Inc UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
AU2007254859A1 (en) 2006-06-01 2007-12-13 Receptor Logic, Ltd Antibodies as T cell receptor mimics, methods of production and uses thereof
RU2495882C2 (en) 2006-09-08 2013-10-20 Медиммун, Ллк. Humanised cd19 antibodies and using them for treating transplantation-related oncological and autoimmune disease
US8629245B2 (en) 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
EA020327B1 (en) 2008-06-25 2014-10-30 Атеникс Корпорейшн Toxin genes and methods for their use
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US20100153133A1 (en) 2008-12-16 2010-06-17 International Business Machines Corporation Generating Never-Event Cohorts from Patient Care Data
US20110311517A1 (en) 2009-02-10 2011-12-22 Shenogen Pharma Group, Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US20120251579A1 (en) 2009-07-30 2012-10-04 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Compositions for generating an antigen specific immune response
WO2011048503A2 (en) 2009-10-22 2011-04-28 Moro Ricardo J Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP2552959B1 (en) 2010-03-26 2017-01-11 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
EA201391449A1 (en) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер ANTIBODIES AGAINST CYTOSOL PEPTIDES
US10239952B2 (en) 2011-04-01 2019-03-26 Memorial Sloan Kettering Cancer Center Anti-WT1/HLA bi-specific antibody
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN104379741B (en) 2012-04-23 2021-07-20 基因先端领域株式会社 Anti-human CD69 antibodies and their use for medical purposes
CN103319595B (en) 2012-07-04 2016-12-28 中国药科大学 Anti-human AFP single-chain antibody and the preparation method and application of fused antigen peptide
ES2786263T3 (en) 2012-07-13 2020-10-09 Univ Pennsylvania Enhancement of T-lymphocyte CAR activity by co-introduction of a bispecific antibody
WO2014014796A1 (en) * 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
EP2893004B1 (en) 2012-09-04 2018-10-24 Cellectis Multi-chain chimeric antigen receptor and uses thereof
EP2903637B1 (en) 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN102993305B (en) 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
CN104968491A (en) 2013-02-06 2015-10-07 旭硝子株式会社 Transparent surface material and display device using same
CN103965362B (en) 2013-02-06 2019-02-01 上海细胞治疗集团有限公司 A kind of chimeric chemokine receptor for making T cell tend to tumor locus
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
WO2014153470A2 (en) 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
KR101536668B1 (en) 2013-06-18 2015-07-15 사회복지법인 삼성생명공익재단 Antibodies cross-reactive to Human and Mouse c-Met and Uses thereof
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
ES2742224T3 (en) 2013-11-07 2020-02-13 Memorial Sloan Kettering Cancer Center Bispecific anti-WT1 / HLA antibodies
CN104087592B (en) 2014-05-13 2016-01-27 天津医科大学总医院 AFP 158-166specificity TCR gene and transgenic T cells thereof and in-vitro multiplication method and purposes
KR102602417B1 (en) 2014-12-05 2023-11-16 메모리얼 슬로안 케터링 캔서 센터 Antibodies targeting g-protein coupled receptor and methods of use
JP6892822B2 (en) 2014-12-05 2021-06-23 メモリアル スローン ケタリング キャンサー センター Antibodies and methods of use that target B cell maturation antigens
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
KR102618312B1 (en) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 Anti-MUC16 antibody and use thereof
MX2017012352A (en) 2015-04-03 2018-01-26 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof.
KR20170141256A (en) 2015-05-08 2017-12-22 유레카 쎄라퓨틱스, 인코포레이티드 Constructs targeting HPV16-E7 peptide / MHC complexes and uses thereof
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3297671A4 (en) 2015-05-18 2019-02-06 Eureka Therapeutics, Inc. Anti-ror1 antibodies
CN107921127B (en) 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 T cell receptor-like antibodies specific for PRAME peptides
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
SG10202110887PA (en) 2015-06-09 2021-11-29 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
MX2017016838A (en) 2015-06-24 2018-04-10 Eureka Therapeutics Inc Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof.
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
US20200087400A1 (en) 2015-07-22 2020-03-19 Eureka Therapeutics, Inc. Constructs targeting psa peptide/mhc complexes and uses thereof
CA3001910A1 (en) 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
SG10201913247XA (en) 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
CN105331585A (en) 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent
CA3007115A1 (en) 2015-12-04 2017-06-08 Memorial Sloan-Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
WO2017124001A2 (en) 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
WO2018057967A2 (en) 2016-09-23 2018-03-29 Eureka Therapeutics, Inc. Constructs targeting hiv peptide/mhc complexes and uses thereof
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
SG11202009525VA (en) 2018-03-30 2020-10-29 Eureka Therapeutics Inc Constructs targeting cd22 and uses thereof
AU2019288136A1 (en) 2018-06-18 2021-01-07 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
EP3880714A4 (en) 2018-11-16 2022-07-20 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
JP2022531454A (en) 2019-05-08 2022-07-06 メモリアル スローン ケタリング キャンサー センター Humanized antibody against mucin-16 and method of using it

Also Published As

Publication number Publication date
JP2022050431A (en) 2022-03-30
TW202321288A (en) 2023-06-01
EP3365364B1 (en) 2024-04-10
US20180085457A1 (en) 2018-03-29
ES2979220T3 (en) 2024-09-24
JP2024062997A (en) 2024-05-10
CN107614519A (en) 2018-01-19
WO2017070608A1 (en) 2017-04-27
US11976105B2 (en) 2024-05-07
US11421013B2 (en) 2022-08-23
MY194628A (en) 2022-12-07
CN107614519B (en) 2022-08-05
JP7316042B2 (en) 2023-07-27
HK1248243A1 (en) 2018-10-12
CA3001137A1 (en) 2017-04-27
PH12018500861A1 (en) 2018-11-05
US10464988B2 (en) 2019-11-05
RU2022103665A (en) 2022-03-05
US20190248865A1 (en) 2019-08-15
RU2018118652A3 (en) 2021-01-29
SG10201913247XA (en) 2020-02-27
CN116059316A (en) 2023-05-05
KR20180063325A (en) 2018-06-11
HK1258274A1 (en) 2019-11-08
CN115927191A (en) 2023-04-07
US20220348629A1 (en) 2022-11-03
MX2018004721A (en) 2018-07-06
US20210253665A1 (en) 2021-08-19
DK3365364T5 (en) 2024-09-30
RU2767209C2 (en) 2022-03-16
AU2016342041B2 (en) 2021-12-02
IL295398A (en) 2022-10-01
US10098951B2 (en) 2018-10-16
IL258405B (en) 2022-09-01
IL314725A (en) 2024-10-01
DK3365364T3 (en) 2024-05-06
TW201730208A (en) 2017-09-01
US20200115434A1 (en) 2020-04-16
EP3365364A4 (en) 2019-08-07
US10822389B2 (en) 2020-11-03
AU2016342041A1 (en) 2018-04-19
IL258405A (en) 2018-05-31
RU2018118652A (en) 2019-11-26
EP3842450A1 (en) 2021-06-30
AU2022201334A1 (en) 2022-03-31
SG10201913245UA (en) 2020-02-27
IL295398B1 (en) 2024-09-01
CN115925973A (en) 2023-04-07
TWI780031B (en) 2022-10-11
EP3365364A1 (en) 2018-08-29
US20190022216A1 (en) 2019-01-24
JP2019500848A (en) 2019-01-17

Similar Documents

Publication Publication Date Title
HK1258274A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201913579WA (en) Chimeric antibody/t-cell receptor constructs and uses thereof
IL274921A (en) Bcma-targeting chimeric antigen receptor, and uses thereof
EP3564266A4 (en) Novel chimeric antigen receptor and use thereof
IL254254A0 (en) Chimeric antigen receptor
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
EP3256492A4 (en) Bi-specific chimeric antigen receptor and uses thereof
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
GB201503742D0 (en) Chimeric antigen receptor
SG11201606790XA (en) Chimeric antigen receptor
GB201607968D0 (en) Chimeric antigen receptor
EP3347474A4 (en) Chimeric antigen receptors and uses thereof
GB201610512D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
GB201709508D0 (en) Chimeric antigen receptor
GB2585607B (en) Chimeric antigen receptor and application thereof
GB201519900D0 (en) Chimeric antigen receptor
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201721421D0 (en) Chimeric antigen receptor
AU2015903719A0 (en) Chimeric antigen receptor and uses thereof
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor
GB201604387D0 (en) Chimeric antigen receptor
AU2014902457A0 (en) Chimeric antigen receptor and uses thereof
GB201409761D0 (en) Chimeric antigen receptor